LRFN2 Antibody
| Code | Size | Price |
|---|
| PSI-5067-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5067-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LRFN2 Antibody: SALM1, FIGLER2, KIAA1246, SALM1, Leucine-rich repeat and fibronectin type-III domain-containing protein 2, Synaptic adhesion-like molecule 1
Application Note:
LRFN2 antibody can be used for detection of LRFN2 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse and rat samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse and rat samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
LRFN2 Antibody: LRFN2 is one of a family of five transmembrane glycoproteins that are highly expressed in neuronal tissues. LRFN proteins share leucine-rich repeat (LRR)-immunoglobulin-like (Ig)-fibronectin type III (Fn)-transmembrane domain structure with other members of the LRR-Ig-Fn protein superfamily such as the Slitrk family of proteins. Expression of LRFN1, -3, and -4 mRNA was detected in embryonic neuronal cells, while Lrfn2 and Lrfn5 expression was primarily restricted to more mature cells. LRFN1, -2, and -4 bound to PDZ domains of postsynaptic PSD95, re-distributing PSD95 to the cell periphery. It has been suggested that the Lrfn proteins play a role in the developing and/or mature vertebrate nervous system.
Background References:
- Morimura N, Inoue T, Katayama K, et al. Comparative analysis of structure, expression and PSD95-binding capacity of Lrfn, a novel family of neuronal transmembrane proteins. Gene2006; 380:72-83.
- Kobe B and Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol.2001; 11:725-32.
- Aruga J and Mikoshiba K. Identification and characterization of Slitrk, a novel transmembrane protein family controlling neurite outgrowth. Mol. Cell Neurosci.2003; 24:117-29.
Buffer:
LRFN2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
LRFN2 antibody was raised against a 14 amino acid synthetic peptide near the carboxy terminus of human LRFN2.
The immunogen is located within amino acids 700 - 750 of LRFN2.
The immunogen is located within amino acids 700 - 750 of LRFN2.
NCBI Gene ID #:
57497
NCBI Official Name:
leucine rich repeat and fibronectin type III domain containing 2
NCBI Official Symbol:
LRFN2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 90 kDa
Observed: 100 kDa?
Observed: 100 kDa?
Protein Accession #:
Q9ULH4
Protein GI Number:
62286951
Purification:
LRFN2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience
SPECIFICITY:
At least two isoforms of LRFN2 are known to exist. This antibody is predicted to not cross-react with other members of the LRFN family.
Swissprot #:
Q9ULH4
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LRFN2 Peptide | PSI-5067P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|